Dakota Drug, Inc.

Dakota Drug, Inc. is a self-certified small disadvantaged business headquartered in Anoka, Minnesota, that has been registered as a federal contractor since June 2001. The company specializes in supplying pharmaceutical products and medical equipment to federal agencies, with a particular focus on supporting U.S. Armed Forces medical operations. Dakota Drug operates as a for-profit Subchapter S Corporation and serves as a critical vendor within the federal healthcare procurement marketplace, providing an extensive range of medications and medical supplies directly to defense healthcare facilities through established relationships with the Defense Logistics Agency.

Through its federal contract awards, Dakota Drug has demonstrated significant capability in delivering diverse pharmaceutical products across multiple therapeutic categories. The company has received numerous delivery orders from the Defense Logistics Agency, primarily for medications including diabetes management products, respiratory treatments, pain management drugs, cardiovascular medications, neurological prescriptions, hormonal treatments, vaccines, and medical supplies. Notable pharmaceutical deliveries include Entresto (cardiovascular medication), Lidocaine patches (topical pain management), Mesalamine (gastrointestinal anti-inflammatory), Trelegy Ellipta (respiratory maintenance medication), epinephrine auto-injectors (emergency medical supplies), and various other critical medications. All identified contract awards were issued by the Defense Logistics Agency with no set-aside designations applied. These delivery orders were executed as individual task orders under the company's larger indefinite delivery contract vehicle, reflecting the efficiency of Dakota Drug's ongoing relationship with DLA for routine pharmaceutical procurement supporting military medical operations.

Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC SPE2DB24D8001) valued at $999,999,999.00 awarded by the Defense Logistics Agency on June 6, 2024, with performance extending through December 31, 2025. This contract falls under DLA Troop Support Medical's ECAT Generation V Program, sourced from solicitation SPE2DH-21-R-0002, which authorizes procurement of commercial medical equipment, accessories, consumables, and medical simulation equipment. Under this comprehensive IDC vehicle, Dakota Drug provides a broad spectrum of pharmaceutical products and medical supplies to support U.S. Armed Forces medical operations across defense healthcare facilities. The contract represents an unrestricted, no-set-aside procurement that enables the Defense Logistics Agency to efficiently issue individual delivery orders for specific medications and medical items as required, with each delivery order typically featuring firm fixed pricing and expedited completion timelines. This single-award IDC demonstrates Dakota Drug's strategic importance within the military medical supply chain, as the company serves as the sole awardee under this major procurement vehicle for medical supplies supporting the entire Department of Defense healthcare system.